Literature DB >> 9201257

Expression of TNF-alpha by human plasma cells in chronic inflammation.

N Di Girolamo1, K Visvanathan, A Lloyd, D Wakefield.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory cytokine and mediator of the inflammatory response. It has been implicated in the pathogenesis of many inflammatory disorders, including rheumatoid arthritis (RA), septic shock, and Crohn's disease. Using a specific anti-human TNF-alpha antibody we detected immunoreactivity for this cytokine in the cytoplasm of inflammatory cells in several chronic inflammatory disorders, including RA, scleritis, and polyarteritis nodosa. These cells were identified predominantly as IgG-expressing plasma cells. Lymph nodes from patients with Hodgkin's lymphoma and breast cancer, but not from control subjects, were also found to contain TNF-alpha-positive plasma cells. Cultured EBV-B lymphocytes and a human plasma cell line (ARH-77) when stimulated with phorbol myristate acetate demonstrated cytoplasmic TNF-alpha immunoreactivity. Western blot analysis of cell membranes and conditioned media from both cell types revealed the presence of the 26-kDa membrane-bound from and the 17-kDa soluble from of TNF-alpha, respectively. TNF-alpha was quantitated by enzyme-linked immunosorbent assay and found to be biologically active as determined by the L929 cytotoxicity assay. This is the first demonstration that plasma cells may be capable of modulating immune and inflammatory responses, not only by antibody production, but also by their secretion of a key inflammatory mediator, TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201257     DOI: 10.1002/jlb.61.6.667

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  16 in total

1.  Rheumatoid arthritis and Epstein-Barr virus: a case of living with the enemy?

Authors:  W Ollier
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

2.  Bcl-x(L) expression in vivo in rheumatoid synovium.

Authors:  S Busteed; M W Bennett; C Molloy; A Houston; M A Stone; F Shanahan; M G Molloy; J O'Connell
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

3.  Constitutive and inducible in vivo protein-DNA interactions at the tumor necrosis factor-alpha promoter in primary human T lymphocytes.

Authors:  C Becker; K Barbulescu; S Wirtz; K H Meyer zum Büschenfelde; S Pettersson; M F Neurath
Journal:  Gene Expr       Date:  1999

Review 4.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Infliximab for the treatment of active scleritis.

Authors:  H Nida Sen; Amit Sangave; Keri Hammel; Grace Levy-Clarke; Robert B Nussenblatt
Journal:  Can J Ophthalmol       Date:  2009-06       Impact factor: 1.882

6.  Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.

Authors:  James J Kobie; Bo Zheng; Peter Bryk; Michael Barnes; Christopher T Ritchlin; Darren A Tabechian; Allen P Anandarajah; R John Looney; Ralf G Thiele; Jennifer H Anolik; Andreea Coca; Chungwen Wei; Alexander F Rosenberg; Changyong Feng; John J Treanor; F Eun-Hyung Lee; Ignacio Sanz
Journal:  Arthritis Res Ther       Date:  2011-12-16       Impact factor: 5.156

7.  Association of Sarcopenic Obesity with Higher Serum High-Sensitivity C-Reactive Protein Levels in Chinese Older Males--A Community-Based Study (Taichung Community Health Study-Elderly, TCHS-E).

Authors:  Chuan-Wei Yang; Chia-Ing Li; Tsai-Chung Li; Chiu-Shong Liu; Chih-Hsueh Lin; Wen-Yuan Lin; Cheng-Chieh Lin
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

8.  The anti-inflammatory activity of a novel fused-cyclopentenone phosphonate and its potential in the local treatment of experimental colitis.

Authors:  Dorit Moradov; Helena Shifrin; Efrat Harel; Mirela Nadler-Milbauer; Marta Weinstock; Morris Srebnik; Abraham Rubinstein
Journal:  Gastroenterol Res Pract       Date:  2015-04-09       Impact factor: 2.260

9.  Refractory necrotizing scleritis successfully treated with adalimumab.

Authors:  Lola E Lawuyi; Avinash Gurbaxani
Journal:  J Ophthalmic Inflamm Infect       Date:  2016-10-12

10.  Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm.

Authors:  Yasmin Mair; Yan Zheng; Donghong Cai
Journal:  N Am J Med Sci       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.